Yoo Seong-Ho, Park Young Sik, Kim Hyeong-Ryul, Sung Sook Whan, Kim Joo Hyun, Shim Young Soo, Lee Soong Deok, Choi Yoon-La, Kim Min-Kyung, Chung Doo Hyun
Department of Pathology, Seoul National University College of Medicine, Chongno-gu Yongon-dong 28, Seoul, South Korea.
Lung Cancer. 2003 Nov;42(2):195-202. doi: 10.1016/s0169-5002(03)00287-3.
Caveolin-1, as a major component of caveolae, is involved in the regulation of cell cycle by impacting various signaling pathways. Previous studies of caveolin-1 in cancer showed two contrary results. In most in vitro studies, caveolin-1 played a role as a tumor suppressor. On the other hand, the elevated expression of caveolin-1 was often reported to be associated with poor clinical outcome in human studies. These results indicate differential biological functions of caveolin-1 depending on the development and progression stage of cancer in vivo.
To clarify the correlation between the clinicopathologic profiles of pulmonary squamous cell carcinomas and the expression of caveolin-1, 107 cases of formalin-fixed and paraffin-embedded tissues of pulmonary squamous cell carcinomas were immunohistochemically evaluated for the expression of caveolin-1 by the tissue-array method.
Caveolin-1 was expressed in 34 cases (31.7%) among 107 cases of pulmonary squamous cell carcinoma. The expression of caveolin-1 was statistically correlated with pathologic stage (stage I and II vs. III; P<0.001), pT (T1 and T2 vs. T3 and T4; P=0.001), and pN (N1 vs. N2 and N3; P=0.0143). The patients with caveolin-1 expression in pulmonary squamous cell carcinomas showed a poorer prognosis than those in caveolin-1-negative group (P=0.0345).
The expression of caveolin-1 is significantly correlated with advanced pathologic stage and poor prognosis in pulmonary squamous cell carcinoma. The results of current study suggest that the expression level of caveolin-1 may be a candidate factor for predicting prognosis in patients with pulmonary squamous cell carcinoma.
小窝蛋白-1作为小窝的主要成分,通过影响各种信号通路参与细胞周期的调控。先前关于小窝蛋白-1在癌症中的研究显示了两种相反的结果。在大多数体外研究中,小窝蛋白-1发挥肿瘤抑制作用。另一方面,在人体研究中,经常报道小窝蛋白-1的表达升高与不良临床结局相关。这些结果表明小窝蛋白-1在体内癌症的发生发展阶段具有不同的生物学功能。
为了阐明肺鳞状细胞癌的临床病理特征与小窝蛋白-1表达之间的相关性,采用组织芯片法对107例福尔马林固定石蜡包埋的肺鳞状细胞癌组织进行免疫组织化学评估,检测小窝蛋白-1的表达。
107例肺鳞状细胞癌中,34例(31.7%)表达小窝蛋白-1。小窝蛋白-1的表达与病理分期(Ⅰ期和Ⅱ期与Ⅲ期;P<0.001)、pT(T1和T2与T3和T4;P=0.001)和pN(N1与N2和N3;P=0.0143)具有统计学相关性。肺鳞状细胞癌中表达小窝蛋白-1的患者预后比小窝蛋白-1阴性组差(P=0.0345)。
小窝蛋白-1的表达与肺鳞状细胞癌的晚期病理分期和不良预后显著相关。本研究结果表明,小窝蛋白-1的表达水平可能是预测肺鳞状细胞癌患者预后的一个候选因素。